Predictors and correlates of adherence to combination antiretroviral therapy (cART): meta-analysis

Nienke Langebeek^{1,2}, Elizabeth Gisolf², Peter Reiss¹, Clemens Richter², Mirjam Sprangers¹, Pythia Nieuwkerk¹

Academic Medical Center, Amsterdam, the Netherlands¹ Rijnstate Hospital, Arnhem, the Netherlands²



Background

Insight in predictors/correlates of non-adherence to cART:

- Enable health care providers to tailor their care to patients most in need.
- Guide targets for development of adherence enhancing interventions.

Objectives


- To review current evidence on predictors/correlates of adherence to cART.
- To aggregate findings into quantitative estimates (effect sizes) of their impact on adherence
- To assess the impact of study design features on effect sizes
 - (adherence assessment method, study design, countries' Human Development Index (HDI)).

Methods

- PubMed search
- · Common effect size: d
 - (0.20 small, 0.50 medium, 0.80 large)
- Random effect models with inverse variance weights to pool effect sizes
- · Mixed-effects meta regression
- · Comprehensive Meta Analysis Version 2

Included 207 studies Patients: 103.836

Adherence assessment method



Predictors/correlates of adherence to ART

				erence
Study or Subgroup	Std. Mean Difference	SE	IV, Randen,	95% CI
1.1.1 medium to large effect	ts			
Adherence self efficacy	0.603	0.0656		(+)
1.1.2 small to medium effect	cts			
Current substance use	-0.395	0.047		
Concerns about cART	-0.388	0.072	(+)	
Trust HIV care provider	0.377	0.043		+
Belief necessity /utility	0.357	0.065		+
Depressive symptoms	-0.305	0.024	+	
HIV stigma	-0.282	0.038	+	
Social support	0.237	0.029		+
1.1.3 small effects				
PI in regimen	-0.196	0.038	+	
Daily dosing frequency	-0.193	0.029	+	
Financial constraints	-0.187	0.025	+	
4.4.4				
1.1.4 < small effects			.	
Pill burden	-0.124	0.028	+ .	
Age	0.118	0.015	. +	
Time since HIV diagnosis	-0.116	0.029	+]	
CD4 cell count	-0.015	0.032	✝.	
Male gender	0.081	0.023]+	
Duration of cART	0.003	0.025	†	
				, ,
			-1 -0.5 0	0.5 1
			lower adherence hig	

Countries' Human Development Index as moderator of the predictor-adherence relationship

			Std. Mean Difference	
Study or Subgroup	Std. Mean Difference	SE	IV, Randon, 95% CI	
1.2.1 Age				
medium and low HDI	0.06	0.02	+	
high HDI	0.14	0.02	+	
1.2.2 Daily dosing frequ	iency			
medium and low HDI	-0.31	0.07		
high HDI	-0.15	0.03		
1.2.3 Trust/ satisfaction HIV care provider				
medium and low HDI	0.59	0.09		
high HDI	0.29	0.04	+	
1.2.4 Depressive symp	toms			
medium and low HDI	-0 41	0.05	<u>+</u>	
high HDI	-0.41		I	
nigh noi	-0.27	0.03		
			 	4
			-1 -0.5 0 0.5 1	
			lower adherence higher adherence	

Adherence assessment method and study design as moderators of the predictor-adherence relationship

			Std. Mean Difference
Study or Subgroup	Std. Mean Difference	SE	IV, Random, 95% CI
1.3.1 Age			
method EMD	0.278	0.053	+
method not EMD	0.102	0.016	+
1.3.2 Adherence self-ef	ficacy		
method self-report	0.722	0.078	+
method not self-report	0.349	0.118	
1.3.3 Current substance	e use		
correlate	-0.482	0.058	
predictor	-0.251	0.071	
1.3.4 Trust/ satisfaction	HIV care provider		
correlate	0.408		+
predictor	0.172	0.073	
			-1 -0.5 0 0.5 1
			lower adherence higher adherence
			-

Results

Medium effects statistically significant	Small effects statistically significant	No effect
Beliefs in necessity / 1 utility of cART	Social support	CD4 cell count
Trust / satisfaction 1 health care provider	Age, male gender, duration of HIV infection	
Current substance use	Daily dosing frequency, PI containing regimen, pill burden	Duration of cART
Depressive symptoms •	Financial constraints	
HIV stigma		

Conclusions

- Adherence enhancing interventions should target psychological factors
- Simplification of cART regimens expected to have smaller albeit significant effects.
- Trust/satisfaction with health care provider more important influence in countries with low or medium HDI.

Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis

Nienke Langebeek, Elizabeth H Gisolf, Peter Reiss, Sigrid C Vervoort, Thóra B Hafsteinsdóttir, Clemens Richter, Mirjam AG Sprangers and Pythia T Nieuwkerk

http://www.biomedcentral.com/ 1741-7015/12/142